{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T09:40:04Z","timestamp":1739785204201,"version":"3.37.1"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[1994,2,1]],"date-time":"1994-02-01T00:00:00Z","timestamp":760060800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Dutch Organization for Scientific Research","award":["(NWO Grant No. 900-541-191)"],"award-info":[{"award-number":["(NWO Grant No. 900-541-191)"]}]},{"name":"Leo Pharmaceutical Products, Ltd."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[1994,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Bisphosphonates are drugs that suppress osteoclast-mediated bone resorption and are used with increasing frequency in the treatment of skeletal disorders. Therapeutic regimens are largely based on pharmacodynamic information because of difficulties in obtaining and interpreting pharmacokinetic data. We describe here the application of a permanently cannulated rat model, previously used in other areas of endocrine research, to the simultaneous study of pharmacokinetic and pharmacodynamic properties of the newly developed bisphosphonate EB-1053 [1-hydroxy-3-(1-pyrrolidinyl)propylidene-1,1-bisphosphonate]. Two groups of five rats each received daily intravenous injections of [14C]EB-1053 (0.025 and 0.1 mg\/day, respectively); a third group (n = 7) received only normal saline injections and served as control. Treatment was given for at least 20 days. A fourth group (n = 3) received IV injections of the bisphosphonate on three separate occasions. Following IV administration, EB-1053 was rapidly cleared from the circulation. Urinary excretion of radioactivity reached about 55% of the daily administered dose within 48 h and remained at this level during the whole treatment period, indicating continuing retention of the bisphosphonate. Bone resorption, assessed biochemically as the hydroxyproline to creatinine ratio in urine, was suppressed effectively with both doses used. Suppression reached a maximum around day 4 and remained at the same level until the end of treatment. Accumulation of the bisphosphonate in the skeleton was therefore not associated with a cumulative effect on bone resorption. This strongly suggests that in treatment planning a distinction should be made between surface-bound and hence biologically active bisphosphonate from the drug which is incorporated in bone during bone turnover. The rat model used in these studies may also allow the examination of other issues of bisphosphonate pharmacology, such as sequential changes in biochemical parameters of bone metabolism in plasma and urine of the same animal, which are necessary for the planning of long-term therapy with uninterrupted administration of these compounds.<\/jats:p>","DOI":"10.1002\/jbmr.5650090213","type":"journal-article","created":{"date-parts":[[2010,2,3]],"date-time":"2010-02-03T16:29:07Z","timestamp":1265214547000},"page":"241-246","source":"Crossref","is-referenced-by-count":2,"title":["Use of a rat model for the simultaneous assessment of pharmacokinetic and pharmacodynamic aspects of bisphosphonate treatment: Application to the study of intravenous 14C-labeled 1-hydroxy-3-(1-pyrrolidinyl)-propylidene-1,1-bisphosphonate"],"prefix":"10.1093","volume":"9","author":[{"given":"Sietse J.","family":"Koopmans","sequence":"first","affiliation":[{"name":"Clinical Investigation Unit, Department of Endocrinology and Metabolic Diseases, University Hospital, Leiden, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lianne","family":"Van Der Wee-Pals","sequence":"additional","affiliation":[{"name":"Clinical Investigation Unit, Department of Endocrinology and Metabolic Diseases, University Hospital, Leiden, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clemens W.G.M.","family":"L\u00f6wik","sequence":"additional","affiliation":[{"name":"Clinical Investigation Unit, Department of Endocrinology and Metabolic Diseases, University Hospital, Leiden, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Socrates E.","family":"Papapoulos","sequence":"additional","affiliation":[{"name":"Clinical Investigation Unit, Department of Endocrinology and Metabolic Diseases, University Hospital, Leiden, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[1994,2,1]]},"reference":[{"key":"2024013113130774000_bib1","first-page":"319","volume-title":"Bone and Mineral Research, Annual 1","author":"Fleisch","year":"1983"},{"key":"2024013113130774000_bib2","first-page":"525","volume-title":"Clinical Disorders of Bone and Mineral Metabolism","author":"Bijvoet","year":"1989"},{"key":"2024013113130774000_bib3","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/0960-0760(92)90197-Q","article-title":"Modulation of tumour-induced bone resorption by bisphosphonates","volume":"43","author":"Papapoulos","year":"1992","journal-title":"J Steroid Biochem Mol Biol"},{"key":"2024013113130774000_bib4","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1016\/S8756-3282(09)80009-4","article-title":"The use of bisphophonates in the treatment of osteoporosis","volume":"13","author":"Papapoulos","year":"1992","journal-title":"Bone"},{"key":"2024013113130774000_bib5","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/0169-6009(89)90095-0","article-title":"Maintained improvement in calcium balance and bone mineral content in patients with osteoporosis treated with the bisphosphonate APD","volume":"5","author":"Valkema","year":"1989","journal-title":"Bone Miner"},{"key":"2024013113130774000_bib6","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/BF01625440","article-title":"Differential action of pamidronate on trabecular and cortical bone in women with involutional osteoporosis","volume":"1","author":"Fromm","year":"1991","journal-title":"Osteoporosis Int"},{"key":"2024013113130774000_bib7","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1002\/jbmr.5650070815","article-title":"Disodium 1-hydroxy-3-(1-pyrrolidinyl)propylidene-1,1-bisphosphonate (EB-1053) is a potent inhibitor of bone resorption in vitro and in vivo","volume":"7","author":"Van der Pluijm","year":"1992","journal-title":"J Bone Miner Res"},{"key":"2024013113130774000_bib8","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/0031-9384(69)90126-7","article-title":"A method for frequent sampling of blood and continuous infusion of fluids in the rat without disturbing the animal","volume":"4","author":"Steffens","year":"1969","journal-title":"Physiol Behav"},{"key":"2024013113130774000_bib9","first-page":"E825","article-title":"Whole body and hepatic insulin action in normal, starved and diabetic rats","volume":"260","author":"Koopmans","year":"1991","journal-title":"Am J Physiol"},{"key":"2024013113130774000_bib10","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/0003-2697(60)90050-6","article-title":"Specific method for analysis of hydroxyproline in tissue and urine","volume":"1","author":"Prockop","year":"1960","journal-title":"Anal Biochem"},{"key":"2024013113130774000_bib11","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1210\/endo-110-1-198","article-title":"Comprehensive kinetics of triiodothyronine production, distribution and metabolism in blood and tissue pools of the rat using optimized blood sampling protocols","volume":"110","author":"DiStefano","year":"1982","journal-title":"Endocrinology"},{"key":"2024013113130774000_bib12","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1210\/endo-111-1-108","article-title":"Comprehensive kinetics of throxine distribution and metabolism in blood and tissue pools of the rat from only 6 blood samples: Dominance of large, slowly exchanging tissue pools","volume":"111","author":"DeStefano","year":"1982","journal-title":"Endocrinology"},{"key":"2024013113130774000_bib13","first-page":"R651","article-title":"Multiexponential multicompartmental and non-compartmental modeling. Methodological limitations and physiological interpretation","volume":"246","author":"DeStefano","year":"1984","journal-title":"Am J Physiol"},{"key":"2024013113130774000_bib14","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/S0090-9556(25)08972-X","article-title":"Physiological disposition of aledronate, a potent anti-osteolytic bisphosphonate, in laboratory animals","volume":"19","author":"Lin","year":"1991","journal-title":"Drugs Metab Dispos"},{"key":"2024013113130774000_bib15","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1136\/bmj.295.6609.1301","article-title":"Paget's disease of bone: Early and late responses to three different modes of treatment with aminohydroxypropylidene bisphosphonate","volume":"295","author":"Harinck","year":"1987","journal-title":"BMJ"},{"key":"2024013113130774000_bib16","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1002\/jbmr.5650040518","article-title":"Application of an in vitro model and a clinical protocol in the assessment of the potency of a new bisphosphonate","volume":"4","author":"Papapoulos","year":"1989","journal-title":"J Bone Miner Res"},{"key":"2024013113130774000_bib17","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1007\/BF00405079","article-title":"Amylin-induced in vivo insulin resistance in conscious rats: The liver is more sensitive to amylin than peripheral tissues","volume":"34","author":"Koopmans","year":"1991","journal-title":"Diabetologia"},{"key":"2024013113130774000_bib18","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/0304-4165(92)90059-4","article-title":"In vivo insulin responsiveness for glucose uptake and production at eu- and hyperglycemic levels in normal and diabetic rats","volume":"1115","author":"Koopmans","year":"1992","journal-title":"Biochim Biophys Acta"},{"key":"2024013113130774000_bib19","first-page":"265","article-title":"Uptake by bone of pyrophosphate, diphosphonates and their technetium derivatives","volume":"54","author":"Bisaz","year":"1978","journal-title":"Clin Sci Mol Med"},{"key":"2024013113130774000_bib20","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/0041-008X(87)90050-0","article-title":"Distribution of [14C]clodronate (dichloromethylene bisphosphonate) disodium in mice","volume":"89","author":"M\u00f6nkk\u00f6nen","year":"1987","journal-title":"Toxicol Appl Pharmacol"},{"key":"2024013113130774000_bib21","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/0041-008X(72)90007-5","article-title":"Metabolism of disodium ethane-1-hydroxy-1,1-diphosphonate (disodium etidronate) in the rat, rabbit, dog and monkey","volume":"21","author":"Michael","year":"1972","journal-title":"Toxicol Appl Pharmacol"},{"key":"2024013113130774000_bib22","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1172\/JCI115539","article-title":"Bisphosphonate action; aledronate localization in rat bone and effects on osteoclast ultrastructure","volume":"88","author":"Sato","year":"1991","journal-title":"J Clin Invest"},{"key":"2024013113130774000_bib23","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/BF02408534","article-title":"Kinetic studies of bone and mineral metabolism during treatment with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD) in rats","volume":"32","author":"Reitsma","year":"1980","journal-title":"Calcif Tissue Int"},{"key":"2024013113130774000_bib24","first-page":"55","volume-title":"The Role of Phosphonates in Living Systems","author":"Francis","year":"1983"},{"key":"2024013113130774000_bib25","first-page":"1565","article-title":"Distribution of 3-amino-1-hydroxypropane-1,1-diphosphonic acid in rats and effect on rat osteosarcoma","volume":"35","author":"Wingen","year":"1985","journal-title":"Drug Res"},{"key":"2024013113130774000_bib26","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/j.1600-0773.1990.tb00750.x","article-title":"Comparison of the distribution of three bisphosphonates in mice","volume":"66","author":"M\u00f6nkk\u00f6nen","year":"1990","journal-title":"Pharmacol Toxicol"}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjbmr.5650090213","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/9\/2\/241\/56495542\/5650090213.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/9\/2\/241\/56495542\/5650090213.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T09:02:43Z","timestamp":1739782963000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/9\/2\/241-246\/7500698"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1994,2,1]]},"references-count":26,"journal-issue":{"issue":"2","published-online":{"date-parts":[[1994,2,1]]},"published-print":{"date-parts":[[1994,2,1]]}},"URL":"https:\/\/doi.org\/10.1002\/jbmr.5650090213","relation":{},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"type":"print","value":"0884-0431"},{"type":"electronic","value":"1523-4681"}],"subject":[],"published-other":{"date-parts":[[1994,2,1]]},"published":{"date-parts":[[1994,2,1]]}}}